MGUS and Myeloma: What’s the link?

Latest from the Blog

Cancer Keys: Cancer and Dyspepsia

Cancer Keys: Cancer and Dyspepsia

Whilst dyspepsia is commonplace in general practice, it can sometimes be an indicator of stomach or oesophageal cancers. Potential pitfall: Typically, dyspepsia may be associated with common and less serious triggers such as lifestyle factors or stress. With patients...

read more
Cancer Keys: Thrombocytosis and L.E.G.O

Cancer Keys: Thrombocytosis and L.E.G.O

Reactive thrombocytosis can be indicator for several underlying causes, which are either self-limiting or serious. These can include infection (e.g. H.pylori), inflammation, blood loss, anaemia and a number of cancers. Helpful hint Depending on the presentation, NICE...

read more

Related Posts

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

MGUS is a benign condition which does not usually require treatment. However, a small number of patients diagnosed with MGUS will go on to develop myeloma.

Understanding MGUS

Monoclonal gammopathy of undetermined significance (MGUS) is a benign condition characterised by the presence of paraproteins in the blood and/or urine. It doesn’t cause symptoms or require treatment and is usually only diagnosed when patients are investigated for other issues.

While most people with MGUS will not see an effect on their general health, about 1% of patients with MGUS will go on to develop myeloma each year.

Specialist viewpoint

The GatewayC Myeloma – Early Diagnosis course explores MGUS and its relationship with Myeloma in greater detail. GatewayC’s Cancer Lead GP, Dr. Sarah Taylor discusses the significance of this pre-malignant condition with Dr. Neil Rabin, Consultant Haematologist at University College London Hospitals and North Middlesex University Hospital NHS Trust.

What does Myeloma UK say about MGUS and Myeloma ?

MGUS is a condition which resembles myeloma due to the presence of abnormal plasma cells in the bone marrow and paraprotein in the blood and/or urine, but at much lower levels than in myeloma.

Each year around one in 100 MGUS patients will be diagnosed with myeloma and will need treatment. MGUS usually remains stable for many years without progressing to myeloma. Data suggests that if MGUS remains stable for two years then, on average, it will remain stable for 10 years before there is progression to myeloma.*

Cancer Key:

The presence of paraproteins in a patient’s blood or urine doesn’t necessarily mean they have myeloma and could be indicative of MGUS. However, it is important that these patients are sent to a haematologist, so that they can be appropriately investigated and be given advice on what symptoms to look out for.

Find out more: visit the GatewayC Myeloma – Early Diagnosis course here.

Keep up to date: Twitter | Facebook | LinkedIn

* Information from Myeloma UK – MGUS. See link here.

Latest from the Blog

Cancer Keys: Cancer and Dyspepsia

Cancer Keys: Cancer and Dyspepsia

Whilst dyspepsia is commonplace in general practice, it can sometimes be an indicator of stomach or oesophageal cancers. Potential pitfall: Typically, dyspepsia may be associated with common and less serious triggers such as lifestyle factors or stress. With patients...

read more
Cancer Keys: Thrombocytosis and L.E.G.O

Cancer Keys: Thrombocytosis and L.E.G.O

Reactive thrombocytosis can be indicator for several underlying causes, which are either self-limiting or serious. These can include infection (e.g. H.pylori), inflammation, blood loss, anaemia and a number of cancers. Helpful hint Depending on the presentation, NICE...

read more

Related Posts

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.